PL3334760T3 - Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami - Google Patents

Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami

Info

Publication number
PL3334760T3
PL3334760T3 PL16760548T PL16760548T PL3334760T3 PL 3334760 T3 PL3334760 T3 PL 3334760T3 PL 16760548 T PL16760548 T PL 16760548T PL 16760548 T PL16760548 T PL 16760548T PL 3334760 T3 PL3334760 T3 PL 3334760T3
Authority
PL
Poland
Prior art keywords
antibody
capped
uncapped
cysteines
drug conjugation
Prior art date
Application number
PL16760548T
Other languages
English (en)
Inventor
Xiaotian Zhong
Amarnauth Shastrie Prashad
Ronald William Kriz
Tao He
Will SOMERS
Wenge Wang
Leo Joseph LETENDRE
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3334760T3 publication Critical patent/PL3334760T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL16760548T 2015-08-12 2016-08-09 Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami PL3334760T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204005P 2015-08-12 2015-08-12
EP16760548.4A EP3334760B1 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
PCT/IB2016/054789 WO2017025897A2 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Publications (1)

Publication Number Publication Date
PL3334760T3 true PL3334760T3 (pl) 2021-10-11

Family

ID=56855760

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16760548T PL3334760T3 (pl) 2015-08-12 2016-08-09 Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami

Country Status (20)

Country Link
US (2) US10653794B2 (pl)
EP (2) EP3334760B1 (pl)
JP (2) JP6865209B2 (pl)
KR (2) KR102146617B1 (pl)
CN (1) CN107849121B (pl)
AU (1) AU2016305331B2 (pl)
BR (1) BR112018001904A2 (pl)
CA (1) CA2938333A1 (pl)
DK (1) DK3334760T3 (pl)
ES (1) ES2864842T3 (pl)
HK (1) HK1252799A1 (pl)
HR (1) HRP20210579T1 (pl)
HU (1) HUE053956T2 (pl)
IL (1) IL257420B (pl)
MX (1) MX2018001686A (pl)
PL (1) PL3334760T3 (pl)
PT (1) PT3334760T (pl)
RU (2) RU2021101009A (pl)
SI (1) SI3334760T1 (pl)
WO (1) WO2017025897A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2864842T3 (es) * 2015-08-12 2021-10-14 Pfizer Cisteínas de anticuerpos protegidas y no protegidas, y su uso en la conjugación fármaco-anticuerpo
KR102322530B1 (ko) * 2017-02-08 2021-11-05 화이자 인코포레이티드 캡핑된 및 비-캡핑된 항체 시스테인의 대규모 제조 공정 및 치료 단백질 접합에서의 그의 용도
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP4249028B2 (ja) * 2001-12-04 2009-04-02 田辺三菱製薬株式会社 蛋白質の活性化方法
EP1893632B1 (en) * 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP2009538357A (ja) * 2006-05-26 2009-11-05 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 部位特異的ｐｅｇ化法
DE17196350T1 (de) * 2007-07-09 2018-12-27 Genentech, Inc. Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US8623598B2 (en) * 2008-03-19 2014-01-07 Intelligent Bio Systems, Inc. Methods and compositions for inhibiting undesired cleaving of labels
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
EP2483289B1 (en) * 2009-10-02 2019-03-20 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
RU2016105962A (ru) * 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
CA2799540A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2777978A1 (en) 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods
JP6067754B2 (ja) * 2012-02-24 2017-01-25 アルテオジェン インコーポレイテッドＡｌｔｅｏｇｅｎ Ｉｎｃ． システイン残基を含むモチーフが結合した修飾抗体、前記修飾抗体を含む修飾抗体−薬物複合体及びその製造方法
US9018172B2 (en) 2012-09-26 2015-04-28 Massachusetts Institute Of Technology Modification of peptides via SNAr reactions of thiols with fluorinated aromatics
WO2015065954A1 (en) * 2013-11-04 2015-05-07 Pfizer, Inc. Anti-efna4 antibody-drug conjugates
WO2015085003A1 (en) * 2013-12-04 2015-06-11 Immunogen, Inc. Compositions and methods for antibody production
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
CA2923862C (en) 2015-03-20 2024-02-13 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
ES2864842T3 (es) * 2015-08-12 2021-10-14 Pfizer Cisteínas de anticuerpos protegidas y no protegidas, y su uso en la conjugación fármaco-anticuerpo

Also Published As

Publication number Publication date
KR20200100850A (ko) 2020-08-26
CN107849121B (zh) 2021-11-09
US11980669B2 (en) 2024-05-14
IL257420B (en) 2022-08-01
HUE053956T2 (hu) 2021-08-30
SI3334760T1 (sl) 2021-07-30
WO2017025897A2 (en) 2017-02-16
HK1252799A1 (zh) 2019-06-06
MX2018001686A (es) 2019-01-31
EP3334760A2 (en) 2018-06-20
KR102146617B1 (ko) 2020-08-20
JP2021118694A (ja) 2021-08-12
AU2016305331B2 (en) 2019-05-16
JP2018525990A (ja) 2018-09-13
DK3334760T3 (da) 2021-04-19
US20200230256A1 (en) 2020-07-23
IL257420A (en) 2018-06-28
BR112018001904A2 (pt) 2018-09-18
RU2742260C2 (ru) 2021-02-04
US10653794B2 (en) 2020-05-19
EP3334760B1 (en) 2021-03-10
PT3334760T (pt) 2021-04-23
RU2018105128A3 (pl) 2020-07-27
JP6865209B2 (ja) 2021-04-28
RU2018105128A (ru) 2019-09-12
US20190030183A1 (en) 2019-01-31
CA2938333A1 (en) 2017-02-12
EP3808768A1 (en) 2021-04-21
HRP20210579T1 (hr) 2021-05-28
KR102319622B1 (ko) 2021-11-02
AU2016305331A1 (en) 2018-02-15
ES2864842T3 (es) 2021-10-14
KR20180038041A (ko) 2018-04-13
RU2021101009A (ru) 2021-02-20
CN107849121A (zh) 2018-03-27
WO2017025897A3 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
HK1243414A1 (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
IL267323A (en) Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
IL247248A0 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
IL248239A0 (en) Drug conjugates - antibody against - her3, preparations containing them and their uses
HK1252799A1 (zh) 封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途
HK1254864A1 (zh) Hbed-二膦酸鹽/酯、其放射金屬軛合物和它們作為治療診斷劑的用途
GB2562059B (en) Improvements in and relating to barriers
ZA201908091B (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
IL249453A0 (en) Texapyrin conjugates and preparations - pt(iv) for use in overcoming resistance to platinum
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
IL266112A (en) Antibodies against edb and antibody-drug conjugates
HUE052751T2 (hu) Natív OMV-antigén konjugátumok és alkalmazásuk
EP3632906C0 (en) AZAARYL DERIVATIVE, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF FOR USE IN PHARMACY
GB201717966D0 (en) Immunotoxins, formulations thereof and their use in medicine
ZA201706254B (en) Oil blends, processes for the preparation thereof and their use in formulas
RS56132B1 (sr) Grupa za lepljenje sa uređajem za podesivi pristup kod laminator-utiskivača, odnosni laminator-utiskivač i postupak za podešavanje pristupa
FI20165821L (fi) Menetelmä fysikaalisten suureitten mittaamiseksi ja menetelmässä hyödynnettävä mittausjärjestely
EP3385281A4 (en) ANTIBODY FOR CROSS-LINKING TO HUMAN SEMA3A AND MOUSE, AND USE THEREOF
IL237283A0 (en) Dldh and its derivatives, and preparations containing them for medical use
METROPOLIS THE SOCIAL AND THE NATIONAL QUESTION IN THE EASTERN METROPOLIS
GB201712096D0 (en) Immunogenic conjugates and use thereof
GB201609866D0 (en) Antibodies, uses thereof and conjugates thereof